Actionable news
All posts from Actionable news
Actionable news in BIIB: Biogen Idec Inc.,

What to Pay Attention to When Biogen (BIIB) Releases Earnings

NEW YORK (TheStreet) -- Biogen (BIIB - Get Report) is scheduled to release its third quarter fiscal 2015 earnings results before the opening bell on Wednesday.

Based in Cambridge, MA, Biogen discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the U.S. and internationally.

For the latest quarter, analysts are expecting the company to earn $3.67 a share on revenue of $2.64 billion.

Exclusive Look Inside: You see Jim Cramer on TV. Now, see where he invests his money. Check out his multi-million dollar portfolio and discover which stocks he is trading. Click here to see the holdings for 14-days FREE.

In the third quarter of fiscal 2014, the company earned $3.62 a share on revenue of $2.51 billion.

Despite the year-over-year earnings growth, the company has been pressured by slowing revenue growth for its multiple sclerosis drug Tecfidera, which is its biggest selling product.

Additionally, the media has been criticizing some biopharma companies for putting high price tags on drugs.

For instance, Biogen's decades-old multiple sclerosis drug Avonex is currently priced at more than $60,000 a year, up from less than $10,000 a year, its first price tag when it got approved in 1996, TheStreet's Adam...